Literature DB >> 2427093

Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides.

D G Malone, A M Irani, L B Schwartz, K E Barrett, D D Metcalfe.   

Abstract

Thirty-five synovial fluid (SF) specimens were examined for the presence of mast cells and for their histamine content. Mast cells were seen in SF cells from 27 of 35 fluids, and histamine was measurable in 19 of 34. There was a strong correlation between mast cell number and histamine content. No consistent relationship was found between either the mast cell number or histamine level and the patients' diagnoses, except that the 2 patients with systemic mastocytosis had markedly elevated values for both SF mast cell number and histamine content. SF mast cells from one of the mastocytosis patients were studied for histamine release; significant amounts of histamine were released upon exposure to anti-human IgE, but not compound 48/80. Thus, mast cells similar to those present in connective tissue are frequently present in SF in numbers which correlate with SF histamine levels. These mast cells contain active proteases and are capable of degranulation. Mast cells were consistently present in large numbers in the SF of patients with systemic mastocytosis, but their numbers were highly variable in fluids of patients with other diseases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427093     DOI: 10.1002/art.1780290803

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

1.  Evidence for both histamine H1 and H2 receptors on human articular chondrocytes.

Authors:  D J Taylor; D E Woolley
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

2.  Characterization of mast cell populations using different methods for their identification.

Authors:  Dmitri Atiakshin; Vera Samoilova; Igor Buchwalow; Werner Boecker; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2017-02-27       Impact factor: 4.304

3.  Experimental arthritis in rats induced by intra-articular injection of IgE aggregates: evidence for arthritogenic role of complexed IgE.

Authors:  L S de Clerck; N J Struyf; C H Bridts; E A van Marck; F C Breedveld; E Devries; H Bazin; W J Stevens
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and -13 zymogens.

Authors:  Natalia J Magarinos; Katherine J Bryant; Amanda J Fosang; Roberto Adachi; Richard L Stevens; H Patrick McNeil
Journal:  J Immunol       Date:  2013-06-24       Impact factor: 5.422

Review 5.  Mast cell chymase: morphofunctional characteristics.

Authors:  Dmitri Atiakshin; Igor Buchwalow; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2019-08-08       Impact factor: 4.304

6.  Mast cell activation in human synovium explants by calcium ionophore A23187, compound 48/80, and rabbit IgG anti-human IgE, but not morphine sulfate.

Authors:  J W Verbsky; P K McAllister; D G Malone
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

7.  Effect of histamine on the production of matrix metalloproteinases-1, -3, -8 and -13, and TNFalpha and PGE(2) by human articular chondrocytes and synovial fibroblasts in vitro: a comparative study.

Authors:  Lynne C Tetlow; David E Woolley
Journal:  Virchows Arch       Date:  2004-09-17       Impact factor: 4.064

8.  Serum IgE anti-cartilage collagen antibodies in rheumatoid patients.

Authors:  J S Bartholomew; J M Evanson; D E Woolley
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

Review 9.  Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.

Authors:  B M Jensen; C Akin; A M Gilfillan
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

10.  IgE rheumatoid factors: quantification in synovial fluid and ability to induce synovial mast cell histamine release.

Authors:  B Gruber; D Ballan; P D Gorevic
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.